ZURICH (Reuters) -Switzerland’s Roche will purchase U.S. biopharma agency Poseida Therapeutics in a money deal price as much as $1.5 billion, the businesses mentioned on Tuesday.
Poseida is to be purchased at $9 per share in money, and stockholders may also obtain a non-tradeable contingent worth proper for as much as $4 per share if particular milestones are met, taking the deal worth to as much as round $1.5 billion.
It’s anticipated to shut within the first quarter of 2025.
“We now have labored intently with Roche by our collaboration targeted on hematologic malignancies, and we’re excited to hitch Roche to work as colleagues collectively throughout our pipeline and future applications,” mentioned Kristin Yarema, president and CEO of the San Diego-based Poseida, in a press release.
Poseida and its staff will be a part of Roche as a part of the Swiss agency’s prescribed drugs division, Poseida mentioned.
The acquisition will set up a brand new functionality for Roche in allogeneic cell remedy, with alternatives targeted on CAR-T applications lined by current collaboration between Poseida and Roche in hematologic malignancies, the U.S. agency mentioned.
It would embrace CAR-T applications for strong tumours and autoimmune ailments, together with Poseida’s genetic engineering platform and associated pre-clinical medicines, it added.
(Writing by Dave Graham; Enhancing by Tom Hogue and Miranda Murray)
ZURICH (Reuters) -Switzerland’s Roche will purchase U.S. biopharma agency Poseida Therapeutics in a money deal price as much as $1.5 billion, the businesses mentioned on Tuesday.
Poseida is to be purchased at $9 per share in money, and stockholders may also obtain a non-tradeable contingent worth proper for as much as $4 per share if particular milestones are met, taking the deal worth to as much as round $1.5 billion.
It’s anticipated to shut within the first quarter of 2025.
“We now have labored intently with Roche by our collaboration targeted on hematologic malignancies, and we’re excited to hitch Roche to work as colleagues collectively throughout our pipeline and future applications,” mentioned Kristin Yarema, president and CEO of the San Diego-based Poseida, in a press release.
Poseida and its staff will be a part of Roche as a part of the Swiss agency’s prescribed drugs division, Poseida mentioned.
The acquisition will set up a brand new functionality for Roche in allogeneic cell remedy, with alternatives targeted on CAR-T applications lined by current collaboration between Poseida and Roche in hematologic malignancies, the U.S. agency mentioned.
It would embrace CAR-T applications for strong tumours and autoimmune ailments, together with Poseida’s genetic engineering platform and associated pre-clinical medicines, it added.
(Writing by Dave Graham; Enhancing by Tom Hogue and Miranda Murray)
